AMAM:NYE-Ambrx Biopharma Inc. (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 4.00

Change

-0.11 (-2.67)%

Market Cap

USD 0.15B

Volume

1.61K

Avg Analyst Target

USD 6.00 (+49.99%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Ambrx Biopharma Inc. (AMAM) Stock Analysis:
Based on the Ambrx Biopharma Inc. stock forecasts from 2 analysts, the average analyst target price for Ambrx Biopharma Inc. is USD 6.00 over the next 12 months. Ambrx Biopharma Inc.’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Ambrx Biopharma Inc. is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, Ambrx Biopharma Inc.’s stock price was USD 4.00. Ambrx Biopharma Inc.’s stock price has changed by +0.51% over the past week, +0.13% over the past month and 0% over the last year.

About

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

-2.80 (-2.64%)

USD250.18B 34.29 3.53
BHVN Biohaven Pharmaceutical Holdin..

-0.40 (-0.28%)

USD10.02B N/A N/A
DNA Ginkgo Bioworks Holdings

-0.23 (-8.65%)

USD4.72B N/A N/A
RCUS Arcus Biosciences Inc

+0.42 (+2.17%)

USD1.39B 27.28 3.74
MYOV Myovant Sciences Ltd

+0.68 (+7.38%)

USD0.83B N/A N/A
ADCT ADC Therapeutics SA

-0.25 (-3.38%)

USD0.57B -99,999.99 N/A
SIGA SIGA Technologies Inc

-0.10 (-1.34%)

USD0.54B 8.22 4.44
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
ZYME Zymeworks Inc

-0.21 (-3.78%)

USD0.32B 300.20 N/A
LCTX Lineage Cell Therapeutics Inc

+0.03 (+2.68%)

USD0.19B 3.63 N/A

ETFs Containing AMAM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -55.70% 32% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -55.70% 32% F 4% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.15B 71% C- 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.83 81% B- 79% C+
Price / Cash Flow Ratio -3.46 55% F 84% B
EV/EBITDA 0.05 92% A- 97% A+
Management Effectiveness  
Return on Equity -42.24% 67% D+ 6% F
Return on Invested Capital -254.98% 10% F 1% F
Return on Assets -22.00% 65% D 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.60 87% B+ 77% C+
Short Percent 139.23% 3% F 12% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector